Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebselen in Treatment-Resistant Depression
NCT05117710Phase 1Unknown
- Sponsor
- University of Oxford
- Start
- Apr 2021
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ebselen in major depressive disorder (MDD), sponsored by University of Oxford. Primary endpoint: Facial Expression Recognition Task at 7 days. Status: unknown.
02
Drugs
ebselen
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05117710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117710.